Life and disease status of patients with Parkinson ’s disease during and after zero-COVID in China: an online survey
ConclusionsThe COVID-19 pandemic aggravated the motor and non-motor symptoms of PD patients either during or after the zero-COVID policy period. The PD patients also experienced prominent mental health problems, changes in daily activities, and increases in economic and caregiver burdens. The COVID-19 pandemic has changed ways of PD management with increasing demands for online medication purchasing and rehabilitation. (Source: Translational Neurodegeneration)
Source: Translational Neurodegeneration - February 6, 2024 Category: Neurology Source Type: research
The interaction between ageing and Alzheimer's disease: insights from the hallmarks of ageing
AbstractAgeing is a crucial risk factor for Alzheimer ’s disease (AD) and is characterised by systemic changes in both intracellular and extracellular microenvironments that affect the entire body instead of a single organ. Understanding the specific mechanisms underlying the role of ageing in disease development can facilitate the treatment of agein g-related diseases, such as AD. Signs of brain ageing have been observed in both AD patients and animal models. Alleviating the pathological changes caused by brain ageing can dramatically ameliorate the amyloid beta- and tau-induced neuropathological and memory impairments,...
Source: Translational Neurodegeneration - January 23, 2024 Category: Neurology Source Type: research
The therapeutic potential of probucol and probucol analogues in neurodegenerative diseases
AbstractNeurodegenerative disorders present complex pathologies characterized by various interconnected factors, including the aggregation of misfolded proteins, oxidative stress, neuroinflammation and compromised blood –brain barrier (BBB) integrity. Addressing such multifaceted pathways necessitates the development of multi-target therapeutic strategies. Emerging research indicates that probucol, a historic lipid-lowering medication, offers substantial potential in the realm of neurodegenerative disease prevent ion and treatment. Preclinical investigations have unveiled multifaceted cellular effects of probucol, showca...
Source: Translational Neurodegeneration - January 22, 2024 Category: Neurology Source Type: research
Correction: A novel transgenic mouse line with hippocampus-dominant and inducible expression of truncated human tau
(Source: Translational Neurodegeneration)
Source: Translational Neurodegeneration - January 11, 2024 Category: Neurology Source Type: research
Death-associated protein kinase 1 as a therapeutic target for Alzheimer's disease
AbstractAlzheimer ’s disease (AD) is the most prevalent form of dementia in the elderly and represents a major clinical challenge in the ageing society. Neuropathological hallmarks of AD include neurofibrillary tangles composed of hyperphosphorylated tau, senile plaques derived from the deposition of amyloid-β (Aβ ) peptides, brain atrophy induced by neuronal loss, and synaptic dysfunctions. Death-associated protein kinase 1 (DAPK1) is ubiquitously expressed in the central nervous system. Dysregulation of DAPK1 has been shown to contribute to various neurological diseases including AD, ischemic stroke and Par kinson’...
Source: Translational Neurodegeneration - January 9, 2024 Category: Neurology Source Type: research
Increased cysteinyl-tRNA synthetase drives neuroinflammation in Alzheimer ’s disease
ConclusionsThe findings suggest that the neuronal CARS drives neuroinflammation and induces memory deficits, which might be involved in the pathogenesis of AD. (Source: Translational Neurodegeneration)
Source: Translational Neurodegeneration - January 8, 2024 Category: Neurology Source Type: research
Nanotechnology for microglial targeting and inhibition of neuroinflammation underlying Alzheimer ’s pathology
ConclusionsThe AM –NP nanotechnology presents a multifactorial strategy to target pathological Aβ aggregation and arrest the fAβ-mediated pathological progression in microglia and neurons.Graphical Abstract (Source: Translational Neurodegeneration)
Source: Translational Neurodegeneration - January 4, 2024 Category: Neurology Source Type: research
Blockage of VEGF function by bevacizumab alleviates early-stage cerebrovascular dysfunction and improves cognitive function in a mouse model of Alzheimer ’s disease
ConclusionsOur study demonstrated the mechanistic roles of VEGF at the early stage of amyloidopathy and the protective effects of bevacizumab on cerebrovascular function and memory performance in 5 ×FAD mice. These findings also suggest the therapeutic potential of bevacizumab for the early intervention of AD. (Source: Translational Neurodegeneration)
Source: Translational Neurodegeneration - January 3, 2024 Category: Neurology Source Type: research
Parkinson ’s disease and gut microbiota: from clinical to mechanistic and therapeutic studies
AbstractParkinson ’s disease (PD) is one of the most prevalent neurodegenerative diseases. The typical symptomatology of PD includes motor symptoms; however, a range of nonmotor symptoms, such as intestinal issues, usually occur before the motor symptoms. Various microorganisms inhabiting the gastrointestinal tract can profoundly influence the physiopathology of the central nervous system through neurological, endocrine, and immune system pathways involved in the microbiota–gut–brain axis. In addition, extensive evidence suggests that the gut microbiota is strongly associated with PD. This review summariz es the late...
Source: Translational Neurodegeneration - December 15, 2023 Category: Neurology Source Type: research
Supplementation with high-GABA-producing Lactobacillus plantarum L5 ameliorates essential tremor triggered by decreased gut bacteria-derived GABA
ConclusionsThese findings highlight that deficiency of GABA-producing gut microbes plays an essential role in the pathogenesis of ET and that L5 is a promising candidate for treating ET. (Source: Translational Neurodegeneration)
Source: Translational Neurodegeneration - December 13, 2023 Category: Neurology Source Type: research
Novel data-driven subtypes and stages of brain atrophy in the ALS –FTD spectrum
ConclusionsOur findings suggest distinct neurodegenerative subtypes of disease along the ALS –FTD spectrum that can be identified in vivo, each with distinct brain atrophy, clinical, genetic and pathological patterns. (Source: Translational Neurodegeneration)
Source: Translational Neurodegeneration - December 7, 2023 Category: Neurology Source Type: research
Inhibiting tau-induced elevated nSMase2 activity and ceramides is therapeutic in an Alzheimer ’s disease mouse model
ConclusionsPDDC is a first-in-class therapeutic candidate that normalizes elevated brain ceramides and nSMase2 activity, leading to the slowing of tau spread in AD mice. (Source: Translational Neurodegeneration)
Source: Translational Neurodegeneration - December 4, 2023 Category: Neurology Source Type: research
Neuronal and synaptic adaptations underlying the benefits of deep brain stimulation for Parkinson's disease
AbstractDeep brain stimulation (DBS) is a well-established and effective treatment for patients with advanced Parkinson's disease (PD), yet its underlying mechanisms remain enigmatic. Optogenetics, primarily conducted in animal models, provides a unique approach that allows cell type- and projection-specific modulation that mirrors the frequency-dependent stimulus effects of DBS. Opto-DBS research in animal models plays a pivotal role in unraveling the neuronal and synaptic adaptations that contribute to the efficacy of DBS in PD treatment. DBS-induced neuronal responses rely on a complex interplay between the distribution...
Source: Translational Neurodegeneration - November 30, 2023 Category: Neurology Source Type: research
N6-methyladenosine-modified circRIMS2 mediates synaptic and memory impairments by activating GluN2B ubiquitination in Alzheimer's disease
ConclusionsIn conclusion, our study demonstrated that m6A-modified circRIMS2 mediates the synaptic and memory impairments in AD by activating the UBE2K-dependent ubiquitination and degradation of GluN2B via sponging miR-3968, providing novel therapeutic strategies for AD. (Source: Translational Neurodegeneration)
Source: Translational Neurodegeneration - November 28, 2023 Category: Neurology Source Type: research
A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer ’s disease
Trial registrationClinicalTrials.gov Identifier: NCT05821153, Registered April 20 2023, Retrospectively registered,https://classic.clinicaltrials.gov/ct2/show/NCT05821153 (Source: Translational Neurodegeneration)
Source: Translational Neurodegeneration - November 16, 2023 Category: Neurology Source Type: research
